Breast cancer as a systemic disease: a view of metastasis
暂无分享,去创建一个
[1] R. Demicheli,et al. Recurrence dynamics does not depend on the recurrence site , 2008, Breast Cancer Research.
[2] A. Harris,et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[3] P. Rothwell,et al. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.
[4] E. Yagüe,et al. Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients , 2012, British Journal of Cancer.
[5] G. Semenza,et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells , 2012, Proceedings of the National Academy of Sciences.
[6] A. Jemal,et al. Global Cancer Statistics , 2011 .
[7] W. Willett,et al. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Jukkola-Vuorinen,et al. Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer , 2012, Breast Cancer Research and Treatment.
[9] J. O’Shaughnessy. Extending survival with chemotherapy in metastatic breast cancer. , 2005, The oncologist.
[10] H. Kuerer,et al. Invasive lobular carcinoma predicts micrometastasis in breast cancer. , 2012, The Journal of surgical research.
[11] Xin Chen,et al. Granulin–Epithelin Precursor Overexpression Promotes Growth and Invasion of Hepatocellular Carcinoma , 2004, Clinical Cancer Research.
[12] R. Weinberg,et al. Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin , 2008, Cell.
[13] A. Jemal,et al. Breast Cancer Statistics , 2013 .
[14] S. Aparicio,et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. , 2012, The oncologist.
[15] Paula D. Bos,et al. Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.
[16] J. Haerting,et al. Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.
[17] Raghu Kalluri,et al. Fibroblasts in cancer , 2006, Nature Reviews Cancer.
[18] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[19] Erin M. Olson,et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. , 2013, Breast.
[20] S. Bicciato,et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors , 2012, Nature.
[21] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[22] R. Weinberg,et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. , 2007, Cancer research.
[23] P. V. van Diest,et al. Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases , 2012, Cancer.
[24] Michael P. Messenger,et al. Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma , 2012, British Journal of Cancer.
[25] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[26] K. Friese,et al. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients , 2012, Archives of Gynecology and Obstetrics.
[27] P. Carmeliet,et al. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? , 2011, Nature Reviews Clinical Oncology.
[28] R. Eils,et al. Systemic spread is an early step in breast cancer. , 2008, Cancer cell.
[29] Gyan Bhanot,et al. Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines , 2012, PloS one.
[30] R. Dienstmann,et al. Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer , 2012, Drug Safety.
[31] Circulating Tumor Cells as Predictors of Response and Failure in Breast Cancer Patients Treated with Preoperative Chemotherapy , 2013, The International journal of biological markers.
[32] Lodewyk F. A. Wessels,et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response , 2009, Breast Cancer Research and Treatment.
[33] S. Kurtz,et al. Quantitative High-Resolution Genomic Analysis of Single Cancer Cells , 2011, PloS one.
[34] K. Pantel,et al. Molecular mechanisms of metastasis , 2011, Journal of surgical oncology.
[35] E. Scarpi,et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. , 2012, Clinical breast cancer.
[36] R. Supramaniam. New malignancies among cancer survivors: SEER cancer registries, 1973–2000 , 2008, Journal of Epidemiology & Community Health.
[37] C. Ménard,et al. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response , 2012, British Journal of Cancer.
[38] P. Carmeliet,et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.
[39] Vandana Iyer,et al. Estrogen promotes ER-negative tumor growth and angiogenesis through mobilization of bone marrow-derived monocytes. , 2012, Cancer research.
[40] G. Breier,et al. Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients. , 2012, Clinical laboratory.
[41] Chih‐Ping Han,et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer , 2011, Cancer.
[42] A. Richardson,et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. , 2012, Cancer discovery.
[43] I. Martinez-Zubiaurre,et al. Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. , 2012, Experimental and therapeutic medicine.
[44] P. Fasching,et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study , 2012, Breast Cancer Research.
[45] D. Wallwiener,et al. Results of iliac crest biopsies taken from 1465 patients with primary breast cancer , 1998, Journal of Cancer Research and Clinical Oncology.
[46] N. Almog. Molecular mechanisms underlying tumor dormancy. , 2010, Cancer letters.
[47] C. Pugh,et al. Hypoxia and oxidative stress in breast cancer: Hypoxia signalling pathways , 2001, Breast Cancer Research.
[48] J. Thiery,et al. Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.
[49] R. Holle,et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.
[50] Gerhard Christofori,et al. Molecular networks that regulate cancer metastasis. , 2012, Seminars in cancer biology.
[51] X. Zha,et al. The dynamic change of circulating tumour cells in patients with operable breast cancer before and after chemotherapy based on a multimarker QPCR platform , 2012, British Journal of Cancer.
[52] J. Bergh,et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Debra L Winkeljohn. Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.
[54] D. Genovesi,et al. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[55] A. Chambers,et al. Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management , 2007, Journal of cellular biochemistry.
[56] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[57] B. Xu,et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[58] A. Bateman,et al. The granulin gene family: from cancer to dementia , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.
[59] P. Lønning,et al. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival , 2012, Breast Cancer Research.
[60] Tao Wang,et al. Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer , 2012, Clinical Cancer Research.
[61] G. Parmigiani,et al. Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.
[62] R. Walker,et al. The complexities of breast cancer desmoplasia , 2001, Breast Cancer Research.
[63] J. Sachdev,et al. Evolution of bevacizumab-based therapy in the management of breast cancer. , 2008, Clinical breast cancer.
[64] Ahmedin Jemal,et al. Breast cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.
[65] L. Livi,et al. Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience , 2013, Medical Oncology.
[66] J. Cuzick,et al. Aspirin and cancer risk: a quantitative review to 2011. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[67] A. Goldhirsch,et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. , 2012, Clinical breast cancer.
[68] Kshitiz,et al. Erratum: Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis (Journal of Clinical Investigation (2013) 123: 1 (189-205) DOI: 10.1172/JCI64993) , 2013 .
[69] G. Semenza,et al. Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer , 2012, PloS one.
[70] R. Hoover,et al. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. , 2006 .
[71] S. Braun,et al. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.
[72] R. Demicheli,et al. Recurrence and mortality according to Estrogen Receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast , 2010, BMC Cancer.
[73] P. Goss,et al. Putative growth characteristics of micrometastatic breast cancer , 2008, Breast Cancer Research.
[74] Jay W. Shin,et al. Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor , 2012, International journal of oncology.
[75] A. Levchenko,et al. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. , 2012, The Journal of clinical investigation.
[76] T. Fehm,et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients , 2008, Breast Cancer Research.
[77] L. Harris,et al. Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer , 2012, Breast Cancer Research and Treatment.
[78] Anne E Carpenter,et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. , 2011, The Journal of clinical investigation.
[79] G. Lorusso,et al. New insights into the mechanisms of organ-specific breast cancer metastasis. , 2012, Seminars in cancer biology.
[80] J. Folkman. Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.
[81] E. Kraynov,et al. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer , 2012, Journal of Experimental & Clinical Cancer Research.
[82] J. Reuben,et al. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome , 2012, BMC Cancer.
[83] J. Folkman,et al. Tumor dormancy due to failure of angiogenesis: role of the microenvironment , 2008, Clinical & Experimental Metastasis.
[84] King-Jen Chang,et al. Molecular Characteristics and Metastasis Predictor Genes of Triple-Negative Breast Cancer: A Clinical Study of Triple-Negative Breast Carcinomas , 2012, PloS one.
[85] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.